[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity
This varies depending on your individual needs and the recommendations of your healthcare provider
As your body becomes used to the drug, these symptoms normally disappear
Buache E, Velard F, Bauden E, Guillaume C, Jallot E, Nedelec JM, Laquerriere P (2012) Effect of strontium-substituted biphasic calcium phosphate on inflammatory mediators production by human monocytes
